FSGS, sNDA and FILSPARI
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...
Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspari drug for rare kidney ...
Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating ...
We recently published a list of These 10 Companies Led Tuesday’s Charge. In this article, we are going to take a look at ...
Shortly after claiming FDA approval for its Filspari therapy for rare kidney disease IgA Nephropathy (IgAN), Travere Therapeutics has said it will price the drug at a discount to a recently ...
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA ...
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback